Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

98.18
+1.831.89%
Volume:292.89K
Turnover:28.25M
Market Cap:6.55B
PE:-31.61
High:98.45
Open:96.92
Low:95.00
Close:96.35
52wk High:122.20
52wk Low:45.91
Shares:66.74M
Float Shares:53.42M
Volume Ratio:1.25
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:44.03
PE(LYR):-22.63

Loading ...

Rhythm Pharmaceuticals Director Camille Bedrosian Resigns

Reuters
·
Dec 20, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Dec 17, 2025

Chief Human Resources Officer Pamela J. Cramer Reports Sale of Rhythm Pharmaceuticals Common Shares

Reuters
·
Dec 16, 2025

Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says

MT Newswires Live
·
Dec 13, 2025

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating

MT Newswires Live
·
Dec 12, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Dec 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill

Reuters
·
Dec 11, 2025

Rhythm Pharmaceuticals Shares up 12% After Positive Mid-Stage Data for Rare Disease Therapy

THOMSON REUTERS
·
Dec 11, 2025

BUZZ-Rhythm Pharma rises on positive mid-stage data for rare disease therapy

Reuters
·
Dec 11, 2025

BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome

Reuters
·
Dec 11, 2025

Rhythm Pharmaceuticals Inc - Plans Phase 3 Trial for Setmelanotide in Pws

THOMSON REUTERS
·
Dec 11, 2025

Rhythm Pharmaceuticals Inc: Safety and Tolerability Results Have Been Consistent With Setmelanotide's Well-Established Clinical Profile

THOMSON REUTERS
·
Dec 11, 2025

Rhythm Pharmaceuticals Announces Preliminary Phase 2 Data for Setmelanotide in Prader-Willi Syndrome

Reuters
·
Dec 11, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data From Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

THOMSON REUTERS
·
Dec 11, 2025

The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com

Dow Jones
·
Dec 05, 2025

Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating

Simply Wall St.
·
Nov 29, 2025

How Positive Analyst Coverage at Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story

Simply Wall St.
·
Nov 27, 2025

Rhythm Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Nov 25, 2025

Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target

MT Newswires Live
·
Nov 25, 2025

Rhythm Pharmaceuticals initiated with a Buy at Citi

TIPRANKS
·
Nov 25, 2025